Published in J Clin Invest on July 01, 1983
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med (1992) 10.08
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun (1985) 4.56
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med (1999) 2.51
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes. Infect Immun (1988) 1.89
Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infect Immun (1999) 1.88
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains. Infect Immun (1991) 1.84
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Macrophages in resistance to candidiasis. Microbiol Mol Biol Rev (1997) 1.74
Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest (1989) 1.67
Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while gram-negative bacteria preferentially stimulate IL-10 production. Infect Immun (2000) 1.60
Oxygen-independent intracellular and oxygen-dependent extracellular killing of Escherichia coli S15 by human polymorphonuclear leukocytes. J Clin Invest (1985) 1.50
Interaction of human leukocytes and Entamoeba histolytica. Killing of virulent amebae by the activated macrophage. J Clin Invest (1985) 1.49
Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun (2009) 1.45
Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med (1987) 1.41
Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun (1992) 1.32
Impairment of the oxidative metabolism of mouse peritoneal macrophages by intracellular Leishmania spp. Infect Immun (1987) 1.31
Role of iron in intracellular growth of Trypanosoma cruzi. Infect Immun (1984) 1.23
Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infect Immun (2004) 1.21
Ingestion and intracellular growth of Mycobacterium paratuberculosis within bovine blood monocytes and monocyte-derived macrophages. Infect Immun (1987) 1.20
Inhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages. Infect Immun (1991) 1.16
Response of Leishmania chagasi promastigotes to oxidant stress. Infect Immun (1994) 1.14
Hydrogen peroxide-mediated toxicity for Leishmania donovani chagasi promastigotes. Role of hydroxyl radical and protection by heat shock. J Clin Invest (1991) 1.13
Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest (1995) 1.12
Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J Infect Dis (2014) 1.09
Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin Exp Immunol (1996) 1.09
Acquisition of iron from transferrin and lactoferrin by the protozoan Leishmania chagasi. Infect Immun (1994) 1.07
Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells. Clin Exp Immunol (1993) 1.07
Cellular defenses against Toxoplasma gondii in newborns. J Clin Invest (1984) 1.05
Biochemistry of the Leishmania species. Microbiol Rev (1988) 1.02
Nonoxidative microbicidal activity in normal human alveolar and peritoneal macrophages. Infect Immun (1987) 1.01
Plasmodium falciparum metacaspase PfMCA-1 triggers a z-VAD-fmk inhibitable protease to promote cell death. PLoS One (2011) 0.95
Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity. J Exp Med (1994) 0.94
Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins. Front Immunol (2014) 0.92
Gamma interferon-activated human macrophages and Toxoplasma gondii, Chlamydia psittaci, and Leishmania donovani: antimicrobial role of limiting intracellular iron. Infect Immun (1991) 0.92
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Cutaneous host defense in leishmaniasis: interaction of isolated dermal macrophages and epidermal Langerhans cells with the insect-stage promastigote. Infect Immun (1988) 0.88
Heterogeneous activity of immature and mature cells of the murine monocyte-macrophage lineage derived from different anatomical districts against yeast-phase Candida albicans. Infect Immun (1986) 0.88
Mechanisms of killing of Toxoplasma gondii by rat peritoneal macrophages. Infect Immun (1986) 0.87
Human endothelial cells are activated by interferon-gamma plus tumour necrosis factor-alpha to kill intracellular Pseudomonas aeruginosa. Immunology (2000) 0.84
Infection of human monocytes by Leishmania results in a defective oxidative burst. Int J Exp Pathol (1994) 0.84
Leishmania amazonensis fails to induce the release of reactive oxygen intermediates by CBA macrophages. Parasite Immunol (2012) 0.82
Axenic Leishmania amazonensis promastigotes sense both the external and internal arginine pool distinctly regulating the two transporter-coding genes. PLoS One (2011) 0.81
Activation of monocytes by interferon-gamma has no effect on the level or affinity of the nicotinamide adenine dinucleotide-phosphate oxidase and on agonist-dependent superoxide formation. J Clin Invest (1988) 0.81
The effects of Con A-induced lymphokines from the T-lymphocyte subpopulations on human monocyte leishmanicidal capacity and H2O2 production. Immunology (1986) 0.81
In vivo-activated mononuclear phagocytes and protective immunity to chlamydiae in mice. Infect Immun (1988) 0.80
Down regulation of macrophage activation in Brugia pahangi-infected jirds (Meriones unguiculatus). Infect Immun (1998) 0.80
Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul. PLoS Negl Trop Dis (2014) 0.78
Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain. PLoS One (2015) 0.76
ALL2, a Homologue of ALL1, Has a Distinct Role in Regulating pH Homeostasis in the Pathogen Cryptococcus neoformans. Infect Immun (2015) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med (1979) 5.38
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med (1979) 5.22
The separation, long-term cultivation, and maturation of the human monocyte. J Exp Med (1977) 4.46
Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest (1981) 4.46
Oxygen-dependent microbial killing by phagocytes (second of two parts). N Engl J Med (1978) 4.31
Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria. J Exp Med (1981) 4.08
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
Bactericidal activity of a superoxide anion-generating system. A model for the polymorphonuclear leukocyte. J Exp Med (1979) 3.19
Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products. J Exp Med (1975) 3.17
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun (1981) 2.88
Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol (1976) 2.79
The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood (1976) 2.76
Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol (1982) 2.42
Multiplication of Leishmania in human macrophages in vitro. Infect Immun (1979) 2.30
The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J Clin Invest (1975) 2.26
Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest (1982) 2.23
Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med (1981) 2.22
Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response. J Immunol (1982) 2.19
Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol (1982) 2.09
Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monocytes and monocyte-derived macrophages. J Reticuloendothel Soc (1980) 1.85
Specific inhibition of lymphocyte-proliferation responses by adherent suppressor cells in diffuse cutaneous leishmaniasis. N Engl J Med (1982) 1.68
Trypanosoma cruzi: induction of microbicidal activity in human mononuclear phagocytes. J Immunol (1982) 1.67
Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes. J Immunol (1981) 1.65
Role for endogenous and acquired peroxidase in the toxoplasmacidal activity of murine and human mononuclear phagocytes. J Clin Invest (1982) 1.64
Formation of multinucleated giant cells from human monocyte precursors. Mediation by a soluble protein from antigen-and mitogen-stimulated lymphocytes. J Exp Med (1982) 1.59
Elimination of Leishmania donovani amastigotes by activated macrophages. Infect Immun (1981) 1.58
Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med (1982) 1.58
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
Experimental cutaneous leishmaniasis. I. Nonspecific immunodepression in BALB/c mice infected with Leishmania tropica. J Immunol (1981) 1.40
A role for oxygen-dependent mechanisms in killing of Leishmania donovani tissue forms by activated macrophages. J Immunol (1982) 1.36
Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med (1981) 1.34
Alterations of the immune response associated with chronic experimental leishmaniasis. Infect Immun (1979) 1.20
Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol (1982) 1.19
Interaction of Leishmania donovani promastigotes with human monocyte-derived macrophages: parasite entry, intracellular survival, and multiplication. Infect Immun (1981) 1.10
Interactions between murine macrophages and obligate intracellular protozoa. Am J Pathol (1981) 0.83
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med (1981) 7.35
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol (1985) 3.85
Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med (1984) 3.73
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Gamma-interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular Chlamydia psittaci replication. J Immunol (1983) 3.49
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med (1975) 3.06
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
Serious infections from Bacillus sp. JAMA (1979) 2.67
Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med (1978) 2.54
Serious infections caused by Streptococcus milleri. Am J Med (1978) 2.47
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol (1982) 2.42
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med (1981) 2.22
Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol (1982) 2.09
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii. J Immunol (1985) 2.00
Lymphokine enhances oxygen-independent activity against intracellular pathogens. J Exp Med (1983) 1.93
Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88
Atypical pneumonias. Med Clin North Am (1980) 1.88
Oxygen-independent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. J Immunol (1986) 1.87
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol (1988) 1.87
Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production. N Engl J Med (1985) 1.87
Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med (1997) 1.80
Malaria--the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med (1992) 1.77
Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm (1979) 1.72
Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med (1981) 1.71
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.69
Regulation of arachidonic acid metabolism by macrophage activation. J Exp Med (1982) 1.69
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Patients treated for amebic liver abscess develop cell-mediated immune responses effective in vitro against Entamoeba histolytica. J Immunol (1986) 1.65
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med (1997) 1.59
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol (2002) 1.54
The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med (1988) 1.51
In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol (1987) 1.51
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. J Immunol (1985) 1.50
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
Septic pulmonary embolism complicating a central venous catheter. Chest (1990) 1.47
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med (1988) 1.45
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol (1994) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med (1981) 1.34
Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis (2002) 1.33
Pretreatment with phorbol myristate acetate inhibits macrophage activity against intracellular protozoa. J Reticuloendothel Soc (1982) 1.32
Coping with AIDS. The special problems of New York City. N Engl J Med (1987) 1.31
Antimicrobial therapy in pulmonary aspiration. Am J Med (1979) 1.31
Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis (2000) 1.29
Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis. J Immunol (1984) 1.25
Effect of hydrocortisone on macrophage response to lymphokine. Infect Immun (1982) 1.23
Combination antibiotic therapy in staphylococcal endocarditis. The use of methicillin sodium-gentamicin sulfate therapy. Arch Intern Med (1976) 1.21
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis (1997) 1.20
Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol (1999) 1.19
Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol (1983) 1.19
The role of gamma interferon in the generation of human macrophages cytotoxic for Entamoeba histolytica trophozoites. Am J Trop Med Hyg (1987) 1.19
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest (1985) 1.15
Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection. Am J Med (1977) 1.14
Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol (1999) 1.13
Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther (1987) 1.10
Staphylococcal septicemia and disseminated intravascular coagulation. Staphylococcus aureus endocarditis mimicking meningococcemia. Arch Intern Med (1977) 1.09
Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis (1995) 1.09
Susceptibility of Entamoeba histolytica to oxygen intermediates. Mol Biochem Parasitol (1981) 1.05
Disseminated paracoccidioidomycosis (South American blastomycosis) in the United States. Am J Med (1974) 1.05
Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis (1989) 1.04
Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis (1996) 1.03
Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis. Infect Immun (1986) 1.02
Fever and pulmonary thromboembolism. Am J Med (1979) 1.01
Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med (1978) 1.00
IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J Immunol (1989) 0.98
Mononuclear phagocyte antimicrobial and antitumor activity: the role of oxygen intermediates. J Invest Dermatol (1980) 0.98
Macrophage activation: enhanced oxidative and antiprotozoal activity. Contemp Top Immunobiol (1984) 0.96
Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis (1994) 0.96
Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol (1998) 0.96
Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS. J Infect Dis (1992) 0.95
Isolated meningitis caused by Blastoschizomyces capitatus. J Infect Dis (1990) 0.95
Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg (2000) 0.94
A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg (1998) 0.94
Disseminated aspergillosis in a renal transplant patient: Diagnostic difficulties re-emphasized. Johns Hopkins Med J (1975) 0.94
Pulmonary mucormycosis: one hundred years later. Chest (1977) 0.94
Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Parasitology (2005) 0.94
Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis (1995) 0.93
Effector role of blood monocytes in experimental visceral leishmaniasis. Infect Immun (1993) 0.92
Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol (1983) 0.91
Fever, rash, and muscle tenderness. A distinctive clinical presentation of disseminated candidiasis. Arch Intern Med (1978) 0.91
Suppression of T-lymphocyte responses to Entamoeba histolytica antigen by immune sera. Infect Immun (1990) 0.90
Preschool programs and later school competence of children from low-income families. Science (1980) 0.90
Circulating interferon-gamma in AIDS patients treated with interleukin-2. N Engl J Med (1988) 0.89